Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $221.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 21.02% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Citigroup raised their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Chardan Capital reissued a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $182.62 on Wednesday. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34. The company has a market cap of $5.25 billion, a price-to-earnings ratio of 103.18 and a beta of 0.84. The business’s 50 day moving average price is $157.18 and its 200 day moving average price is $175.18.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the business posted $0.30 earnings per share. The firm’s revenue was up 116.4% compared to the same quarter last year. On average, analysts predict that Krystal Biotech will post 3.22 EPS for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently modified their holdings of the company. FMR LLC grew its stake in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after buying an additional 21,133 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC boosted its holdings in Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after purchasing an additional 6,600 shares during the period. State Street Corp boosted its holdings in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).